Home › Funds › Orbis Allan Gray Ltd › ALNY
Orbis Allan Gray Ltd position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Orbis Allan Gray Ltd reported holding 2,421,175 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$597.4M, representing 1.99% of its reported portfolio and ranking #19 among its reported holdings. Orbis Allan Gray Ltd has disclosed ALNY holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Orbis Allan Gray Ltd's ALNY position evolved
Orbis Allan Gray Ltd first disclosed a stake in ALNY in Q3 2023 at 38,189 shares (US$6.8M). The position peaked in Q3 2025 at 1,950,962 shares, worth US$889.6M. Across 11 filings, Orbis Allan Gray Ltd increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,421,175 shares valued at US$597.4M — an increase of 433,768 shares quarter over quarter.. Notable position changes include a 76% increase in Q3 2024 (shares fell 14% over the following quarter), a 30% increase in Q2 2025 (shares rose 40% over the following quarter), a 49% increase in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 38.19K | $6.76M | New |
| Q2 2024 | 721.05K | $175.22M | New |
| Q3 2024 | 1.27M | $348.77M | Add |
| Q4 2024 | 1.47M | $346.57M | Add |
| Q1 2025 | 1.63M | $441.46M | Add |
| Q2 2025 | 2.12M | $691.77M | Add |
| Q3 2025 | 1.95M | $889.64M | Reduce |
| Q4 2025 | 1.62M | $643.48M | Reduce |
| Q1 2026 | 1.33M | $441.65M | Reduce |
| Q2 2026 | 1.99M | $598.27M | Add |
| Q3 2026 | 2.42M | $597.40M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), TWO SIGMA ADVISERS, LP (US$450.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
More on Orbis Allan Gray Ltd
FAQ
How long has Orbis Allan Gray Ltd held ALNY?
Orbis Allan Gray Ltd has disclosed ALNY holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is Orbis Allan Gray Ltd's current position in ALNY?
As of Q3 2026, Orbis Allan Gray Ltd holds 2.42M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $597.40M, representing 1.99% of its reported portfolio and ranking #19.
Has Orbis Allan Gray Ltd been buying or selling ALNY?
In the latest 13F filing (Q3 2026), Orbis Allan Gray Ltd increased its position in ALNY. The position peaked in Q3 2025 at 1.95M shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, TWO SIGMA ADVISERS, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.